PRKAA2 and metabolic syndrome: Because changes in the mitochondrial and cellular energy state could lead to a broad spectrum of effects and may cause side effects, direct allosteric activation of AMPK without increasing the cellular AMP/ATP ratios represents a novel therapeutic approach for treating metabolic syndrome.